Revolutionizing Cardiovascular Health in Young Adults: Advancements in Preventing Subclinical Atherosclerosis for a Heart-Healthy Future

Cardiovascular prevention, as the guidelines draw it, begins around age 40. This expert analysis argues that for a growing number of people, that start line is years too late.

The evidence it gathers is uncomfortable. Atherosclerosis — the slow furring of the arteries — is already underway in young adults who look, by every conventional measure, low-risk. In the CARDIA cohort, 21% of adults aged 30 to 45 already had detectable coronary calcium; in the Miami Heart study, nearly a third of those 40 to 54 did. Even risk factors within the “normal” range — a blood pressure under 120, an HbA1c that doesn’t yet spell diabetes — leave a mark when carried for enough years.

The problem is structural. The standard 10-year risk calculator was never validated under age 40, so the very people in whom early plaque is forming fall through a gap in the tools. The authors point instead to lifetime-risk estimation, selective calcium scoring in young adults with multiple risk factors, and the ongoing PRECAD trial, which is testing whether aggressive control of LDL, blood pressure, and glucose in 20-to-39-year-olds slows the disease.

The status-quo tension is explicit: treating healthy young adults runs into adherence problems, thin randomized evidence, and a culture that quietly equates “young” with “safe.”

We rate the evidence moderate. This is an expert synthesis of strong cohort data — CARDIA, PESA, the Copenhagen study — rather than new trial results, and its boldest recommendation, statins before 40, still awaits proof. But the underlying principle, that cumulative exposure is what damages arteries, is well established, and it reframes prevention as something that starts long before the first prescription.